about
MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxisMF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.Immunogenicity of three different influenza vaccines against homologous and heterologous strains in nursing home elderly residentsImmunogenicity and safety of purified chick-embryo cell rabies vaccine under Zagreb 2-1-1 or 5-dose Essen regimen in Chinese children 6 to 17 years old and adults over 50 years: a randomized open-label study.Safety and immunogenicity of an MF59-adjuvanted subunit influenza vaccine in elderly Chinese subjectsShort-Term Immunogenicity and Safety of an Accelerated Pre-Exposure Prophylaxis Regimen With Japanese Encephalitis Vaccine in Combination With a Rabies Vaccine: A Phase III, Multicenter, Observer-Blind Study.Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis.Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study.Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: a phase III, observer-blind, randomized, controlled multicenter study.Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.An update of clinical experience with the quadrivalent meningococcal ACWY-CRM conjugate vaccineCOPD treatment: Real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretionRight-to-Left Shunt in CADASIL PatientsEffect of Sulfhydryl and non-Sulfhydryl Angiotensin-Converting Enzyme Inhibitors on Endothelial Function in Essential Hypertensive PatientsDysautonomic achalasia in two siblings with Sandhoff diseaseResults from a large post-marketing safety surveillance study in the Republic of Korea with a quadrivalent meningococcal CRM-conjugate vaccine in individuals aged 2 months-55 yearsSafety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months oldImmunogenicity of a Quadrivalent Human Papillomavirus Vaccine When Co-Administered with Tetanus-Reduced Diphtheria-Acellular Pertussis and Quadrivalent Meningococcal Conjugate Vaccines in Healthy Adolescents: Results from a Randomized, Observer-BlinOne-year antibody persistence and safety of a 4-dose schedule of MenACWY-CRM in healthy infants from South KoreaMenACWY-CRM conjugate vaccine booster dose given 4-6 years after priming: Results from a phase IIIb, multicenter, open label study in adolescents and adults
P50
Q30377215-EBC4177B-4F3F-4139-BCFE-828223D6FE31Q30380647-30646439-4EE1-436B-B68C-E8A0D49BA09DQ33760887-A5206702-FF39-46A1-9670-4D0274DDE7F3Q35887112-F3DEF369-5AF4-4D1D-BA23-4E345046A1A8Q36535192-8D166BC6-8273-4CBF-80C3-EE8BB753648EQ39103439-EF8EF444-96E2-466D-9CDE-E7E91B9360E0Q42919297-3F592E6D-CC4D-47B2-9463-12E1EE12C15AQ44543899-F6D5BFB4-8B98-4A62-BAFD-DAB8B677BBE8Q46648171-C8C52CAB-6705-4416-ABB3-CFDAB924FEB1Q51186380-E36C0774-C1BE-4DE5-89DA-D20654266210Q55371503-F0005BAD-7E54-45F6-B1F4-046203EF68EAQ57570815-25F2672A-5C32-4F95-812A-2144E72B3973Q57570818-F36DDAEB-2E2B-4AA2-AAD8-97B0AC9A48FCQ57570826-59A690E9-A30B-4FD3-887F-C8996E628601Q57570829-1671198F-6421-43AC-88C3-E9662F8D8629Q57570831-1C821D19-F969-4CC6-8B03-47944F036B84Q90846274-DE634D14-5F94-4457-BE61-CC413D74E495Q90927821-026742F1-B694-4708-9F55-BB5C861ACE18Q92391493-6E62D8B3-A750-4675-90F0-39A8A600BF9EQ92581139-E2B17E5C-AB4E-4832-8F50-9256E98CAAE5Q93178262-471F89BF-A204-4131-B6A8-3AE9FD0AAFF7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
MICHELE PELLEGRINI
@ast
MICHELE PELLEGRINI
@en
MICHELE PELLEGRINI
@es
MICHELE PELLEGRINI
@nl
type
label
MICHELE PELLEGRINI
@ast
MICHELE PELLEGRINI
@en
MICHELE PELLEGRINI
@es
MICHELE PELLEGRINI
@nl
prefLabel
MICHELE PELLEGRINI
@ast
MICHELE PELLEGRINI
@en
MICHELE PELLEGRINI
@es
MICHELE PELLEGRINI
@nl
P106
P1153
7103161953
P31
P496
0000-0001-8505-9260